Skin Disease and Inflammation: Current Treatment and Future Options

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 10 October 2025 | Viewed by 939

Special Issue Editor


E-Mail Website
Guest Editor
Unit of Dermatology, University of “La Sapienza”, 00155 Rome, Italy
Interests: psoriasis; atopic dermatitis; idradenitis; biological treatment; acne
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Outstanding progress has been made in recent decades in dermatology, especially regarding inflammatory skin diseases, which are more common and tend to have a significant impact on patients' quality of life. Chronic inflammatory diseases represent a therapeutic challenge. Today, we have weapons available, as well as many new drugs in the pipeline for various conditions that had no therapy for years.

I would like to invite you to take part in this Special Issue for the journal of Therapeutics of which I am the editor.

The aim of this Special Issue is to publish scientific articles on a variety of topics, but above all, to focus on new therapies in the medical field, biological therapies, target therapies and innovative therapies with exciting data that can help the entire scientific community. The possibility of collecting all this in various publications is the purpose of this Special Issue.

I look forward to receiving your contributions and thank you for your support.

You may choose our Joint Special Issue in Therapeutics.

Dr. Annunziata Dattola
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • eczema
  • psoriasis
  • hidradenitis suppurativa
  • alopecia areata
  • acne
  • atopic dermatitis
  • urticaria
  • prurigo nodularis
  • lichen

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 424 KiB  
Review
Off-Label Treatment in Inflammatory Skin Diseases—European Point of View
by Julia Sternicka, Roman J. Nowicki, Leszek Bieniaszewski and Dorota Purzycka-Bohdan
J. Clin. Med. 2025, 14(7), 2376; https://doi.org/10.3390/jcm14072376 - 30 Mar 2025
Viewed by 593
Abstract
Off-label treatment is the use of a drug approved for marketing, outside the registration in terms of indication, age group, dose or route of administration. Despite the constant appearance of new preparations on the market, treatment outside the SmPCs guidelines is a current [...] Read more.
Off-label treatment is the use of a drug approved for marketing, outside the registration in terms of indication, age group, dose or route of administration. Despite the constant appearance of new preparations on the market, treatment outside the SmPCs guidelines is a current clinical problem. It is believed that it is based on the needs of patients unmet by classical therapy methods. This work focuses on off-label treatment in inflammatory dermatoses such as atopic dermatitis, psoriasis, acne vulgaris and rosacea. Publications on this subject, available on PubMed, Google Scholar and the Cochrane Library, were analyzed in the form of a review, taking into account the mechanisms of action, efficacy and safety of preparations. Based on the literature analysis, it can be concluded that the use of drugs outside the SmPC indications is a common situation in dermatology. However, it is difficult to determine its exact frequency—there is a lack of data on the prevalence of off-label appliances in inflammatory dermatoses from a European perspective. Publications demonstrate varying effectiveness and safety of this form of therapy, depending on the specific preparation. Off-label treatment in dermatology remains an important and current clinical issue that should be explored in further research. Full article
(This article belongs to the Special Issue Skin Disease and Inflammation: Current Treatment and Future Options)
Back to TopTop